State WA
Clinical Trials in Washington
Recruiting clinical trials with at least one study location in Washington. Data updated daily from ClinicalTrials.gov.
Top Conditions in Washington
Colorectal Cancer (8)Breast Cancer (7)Prostate Cancer (7)Malignant Solid Neoplasm (6)Acute Myeloid Leukemia (5)Melanoma (5)Non-small Cell Lung Cancer (5)Acute Lymphoblastic Leukemia (4)Ovarian Cancer (4)Hematopoietic and Lymphatic System Neoplasm (4)Mantle Cell Lymphoma (3)Mixed Phenotype Acute Leukemia (3)
NCT06032273 N/A
Recruiting
Lung Transplant READY CF 2: CARING CF Ancillary RCT
Condition
Cystic Fibrosis
Enrollment
132 pts
Location
United States
Sponsor
University of Washington
NCT03193151 N/A
Recruiting
Diagnostic and Therapeutic Applications of Microarrays in Liver Transplantation
Condition
Liver Dysfunction
Enrollment
300 pts
Location
United States, Australia, Canada
Sponsor
University of Alberta
NCT07104383 Phase 3
Recruiting
VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)
Condition
Weight Loss
Enrollment
1,100 pts
Location
United States, Puerto Rico
Sponsor
Viking Therapeutics, Inc.
NCT06066502 Phase 3
Recruiting
Precision Ventilation vs Standard Care for Acute Respiratory Distress Syndrome
Condition
Acute Respiratory Distress Syndrome
Enrollment
1,100 pts
Location
United States
Sponsor
Beth Israel Deaconess Medical
NCT06136650 Phase 3
Recruiting
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Age...
Condition
Metastatic Castration-resistant Prostate Cancer (mCRPC)
Enrollment
1,314 pts
Location
United States, Australia, Brazil
Sponsor
Merck Sharp & Dohme LLC
NCT05947851 Phase 3
Recruiting
A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Secon...
Condition
Leukemia, Lymphocytic, Chronic, B-Cell
Enrollment
735 pts
Location
United States, Argentina, Australia
Sponsor
Merck Sharp & Dohme LLC
NCT05580562 Phase 3
Recruiting
ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study...
Condition
H3 K27M
Enrollment
450 pts
Location
United States, Argentina, Australia
Sponsor
Jazz Pharmaceuticals
NCT06395519 Phase 1, Phase 2
Recruiting
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
Condition
Advanced or Metastatic Solid Tumors
Enrollment
120 pts
Location
United States
Sponsor
858 Therapeutics, Inc.
NCT07174583 Phase 1, Phase 2
Recruiting
A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell L...
Condition
Small-cell Lung Cancer
Enrollment
208 pts
Location
United States, Australia, Brazil
Sponsor
IDEAYA Biosciences
NCT06683092 N/A
Recruiting
Restarting Triple Therapy With Robust Monitoring for Adverse Events (RETRIAL)
Condition
Cystic Fibrosis
Enrollment
200 pts
Location
United States
Sponsor
Boston Children's Hospital
NCT06384911 N/A
Recruiting
InvesT1D: Promoting Adolescent Investment in Diabetes Care
Condition
Type 1 Diabetes
Enrollment
96 pts
Location
United States
Sponsor
Harvard Pilgrim Health Care
NCT04375631 Phase 1
Recruiting
CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Ce...
Condition
Recurrent Acute Myeloid Leukemia
Enrollment
120 pts
Location
United States
Sponsor
Fred Hutchinson Cancer Center
NCT05905328 Phase 1, Phase 2
Recruiting
Study of CTO1681 for the Prevention and Treatment of CRS in DLBCL Patients Recei...
Condition
Cytokine Release Syndrome
Enrollment
54 pts
Location
United States
Sponsor
CytoAgents, Inc.
NCT06295965 N/A
Recruiting
Clonal Hematopoiesis and Therapy-Emergent Myeloid Neoplasms in Patients With Can...
Condition
Recurrent Fallopian Tube Carcinoma
Enrollment
2,000 pts
Location
United States
Sponsor
University of Washington
NCT06662786 Phase 3
Recruiting
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or ...
Condition
Colorectal Neoplasms
Enrollment
1,000 pts
Location
United States, Belgium, Brazil
Sponsor
Janssen Research & Development
NCT07206056 Phase 1, Phase 2
Recruiting
An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tul...
Condition
Progressive Metastatic Castrate Resistant Prostate Cancer
Enrollment
188 pts
Location
United States, Australia, China
Sponsor
Novartis Pharmaceuticals
NCT05283720 Phase 2
Recruiting
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneou...
Condition
Non-Hodgkin Lymphoma
Enrollment
496 pts
Location
United States, China, Czechia
Sponsor
Genmab
NCT05065372 Phase 1
Recruiting
MANATEE-T1D: Metformin ANd AutomaTEd Insulin Delivery System Effects on Renal Va...
Condition
Type 1 Diabetes
Enrollment
60 pts
Location
United States
Sponsor
Kalie Tommerdahl
NCT02325674 N/A
Recruiting
MEASuRE: Metreleptin Effectiveness And Safety Registry
Condition
Generalised Lipodystrophy
Enrollment
100 pts
Location
United States, France, Germany
Sponsor
Amryt Pharma
NCT05458674 Phase 2
Recruiting
Tucatinib+Trastuzumab+Eribulin in HER2+ MBC
Condition
Breast Cancer
Enrollment
30 pts
Location
United States
Sponsor
Criterium, Inc.
NCT03547973 Phase 2
Recruiting
Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Canno...
Condition
Metastatic Urothelial Cancer
Enrollment
827 pts
Location
United States, France, Germany
Sponsor
Gilead Sciences
NCT05677451 Phase 3
Recruiting
24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, ...
Condition
Chronic Spontaneous Urticaria
Enrollment
100 pts
Location
United States, Argentina, Canada
Sponsor
Novartis Pharmaceuticals
NCT05718102 N/A
Recruiting
Pragmatic Trial to Enhance Quality Safety, and Patient Experience in COPD
Condition
Pulmonary Disease, Chronic Obstructive
Enrollment
4,000 pts
Location
United States
Sponsor
Seattle Institute for Biomedic
NCT01804686 Phase 3
Recruiting
A Long-term Extension Study of PCI-32765 (Ibrutinib)
Condition
Chronic Lymphocytic Leukemia
Enrollment
700 pts
Location
United States, Argentina, Australia
Sponsor
Janssen Research & Development
NCT06725173 N/A
Recruiting
Detailed Phenotypic and Genotype Study to Correlate RB1 Mutations Relating to Pr...
Condition
Retinoblastoma Bilateral
Enrollment
100 pts
Location
United States
Sponsor
University of Washington